Key indicators: single-crystal X-ray study; T = 150 K; mean (C-C) = 0.003 Å; disorder in main residue; R factor = 0.036; wR factor = 0.094; data-to-parameter ratio = 13.6.
In the title compound, C 17 H 20 ClFN 2 O 3 , the dihedral angle between the pyridazine and benzene rings is 41.37 (10) . In the crystal, there are no significant intermolecular interactions present. The terminal -CH 2 F group is disordered over two sets of sites with an occupancy ratio of 0.737 (2):0.263 (2).
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For details of the synthesis, see: Mou et al. (2010 Mou et al. ( , 2012 . For possible applications of the title compound as a myocardial perfusion imaging agent for positron emission tomography (when labelled with 18 F), see: Mou et al. (2011) ; Mou et al. Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: SHELXTL (Sheldrick, 2008); software used to prepare material for publication: SHELXTL. supplementary materials Acta Cryst. (2012) . E68, o1707 [doi:10.1107/S1600536812020491]
2-tert-Butyl-4-chloro-5-[4-(2-fluoroethoxy)benzyloxy]pyridazin-3(2H)-one
Huihui Jing, Tiantian Mou and Xianzhong Zhang Comment Myocardial uptake of the pyridaben analogues, which is correlated with blood flow, makes them potential myocardial perfusion imaging (MPI) agents for the positron emission tomography (PET) when labeled with 18 F (Mou et al., 2010; Mou et al., 2011; Mou et al., 2012) . Thus, the development of pyridaben analogues may lead to discover new valuable PET MPI agents.
The molecular structure of the title compound (measured at 150 K) is shown in Fig. 1 . The dihedral angle between the pyridazine ring and the benzene ring is 41.37 (10)°. The terminal CH 2 F group is disordered between two positions with occupancies 0.737 (2) for C1F1 and 0.263 (2) for C1AF1A.
Experimental
The synthesis route is shown in Fig. 2 . The solution of tert-butylammonium fluoride (1 mmol in 1 ml tetrahydrofuran) was stirred in a stream of nitrogen at 110 °C to remove the solvent. Then 2-tert-butyl-4-chloro-5-(4-(2-tosylethoxy-ethoxy)-benzyloxy)-2H-pyridazin-3-one (compound I, 0.30 mmol in 3 ml anhydrous CH 3 CN) was added to the above evaporation residue, and refluxed for 40 min at 90 °C. After concentration under reduced pressure, the residue was chromatographed over a column of silica gel and eluted with the mixture of dichloromethane and methanol (100:1). The product was obtained as white solid. The product was then recrystallized from the mixture of hexane and methanol (2:1) yielding colorless crystals of the title compound suitable for the single-crystal X-ray diffraction.
Refinement
The H atoms bound to C atoms were positioned geometrically and refined using a riding model, with C-H = 0.99 Å for CH 2 groups, 0.95 Å for aryl and 0.98 Å for methyl H atoms, U iso (H) =1.2U eq (C) for CH 2 groups and aryl, and U iso (H) =1.5U eq (C) for methyl H atoms. 
Computing details

Figure 2
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